Grifols (GIKLY) Other Non-Current Assets (2016 - 2025)

Grifols (GIKLY) reported Other Non-Current Assets of $27.9 million for Q4 2025, down 31.2% on a YoY basis from $40.6 million in Q4 2024, and down 31.2% quarter-over-quarter from $40.6 million in Q4 2024.

Grifols (GIKLY) Other Non-Current Assets (2016 - 2025) Analysis & Trends

Grifols has reported Other Non-Current Assets for 10 years, with the latest figure at $27.9 million in Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 31.2% year-over-year to $27.9 million; the trailing twelve-month figure through Dec 2025 stood at $27.9 million (down 31.2% YoY), and the FY2025 full-year result was $27.9 million, down 31.2% from the prior year.
  • Other Non-Current Assets for Q4 2025 stood at $27.9 million, down from $40.6 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $298.9 million in Q4 2021, with the low at $27.9 million in Q4 2025.
  • Historically, Other Non-Current Assets has averaged $128.0 million across 5 years, with a median of $126.7 million in 2022.
  • Annual changes were most pronounced in 2021 — Other Non-Current Assets soared 132.07% — and 2024, when it slumped 72.17%.
  • Grifols' Other Non-Current Assets stood at $298.9 million in 2021, then plunged by 57.61% to $126.7 million in 2022, then gained by 15.17% to $145.9 million in 2023, then tumbled by 72.17% to $40.6 million in 2024, then sank by 31.2% to $27.9 million in 2025.
  • The last three Other Non-Current Assets figures came in at $27.9 million (Q4 2025), $40.6 million (Q4 2024), and $145.9 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 3.18 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.23 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 14.11 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 10.54 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 19.81 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 12.76 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 4.55 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 9.83 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 6.08 Bn
10 Grifols - - - 27.94 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 27.94 Mn
Dec 31, 2024 40.61 Mn
Dec 31, 2023 145.93 Mn
Dec 31, 2022 126.71 Mn
Dec 31, 2021 298.91 Mn
Dec 31, 2020 128.80 Mn
Sep 30, 2020 147.64 Mn
Mar 31, 2020 145.22 Mn
Dec 31, 2019 32.66 Mn
Sep 30, 2019 133.28 Mn
Mar 31, 2019 137.44 Mn
Dec 31, 2018 2.18 Mn
Sep 30, 2018 78.26 Mn
Mar 31, 2018 75.04 Mn
Dec 31, 2017 77.90 Mn
Dec 31, 2016 1.16 Mn